Publications by authors named "Susan B Manoff"

Claim this Profile
I
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adults.
Susan B Manoff, Michele Sausser, Amy Falk Russell, Jason Martin, David Radley

Hum Vaccin Immunother· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.
Karen L Ciprero, Rocio D Marchese, Patrick Richard, Martine Baudin, Tina M Sterling, Susan B Manoff

Hum Vaccin Immunother· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical development of a dengue recombinant subunit vaccine.
Susan B Manoff, Sarah L George, Andrew J Bett, Michele L Yelmene, Govindarajan Dhanasekaran

Vaccine· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advances in the understanding, management, and prevention of dengue.
Laura L Hermann, Swati B Gupta, Susan B Manoff, Siripen Kalayanarooj, Robert V Gibbons

J Clin Virol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults.
Kathleen M Mullane, Drew J Winston, Michael S Wertheim, Robert F Betts, Donald M Poretz, Susan B Manoff

J Infect Dis· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience.
Fabio Lievano, Susan A Galea, Michele Thornton, Richard T Wiedmann, Susan B Manoff

Vaccine· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults.
John D Grabenstein, Susan B Manoff

Vaccine· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
Daniel M Musher, Susan B Manoff, Richard D McFetridge, Charles L Liss, Rocio D Marchese

Hum Vaccin· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pneumococcal vaccines in adults: assessing the evolving evidence.
John D Grabenstein, Susan B Manoff

Vaccine· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = years.
Susan B Manoff, Charles Liss, Michael J Caulfield, Rocio D Marchese, Jeffrey Silber

J Infect Dis· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis